CIMZIA

Reason for request

Clinical Benefit

Moderate

Moderate in view of the low level of evidence demonstrating its structural effect in the treatment of psoriatic arthritis.

Clinical Added Value

no clinical added value

CIMZIA does not provide any improvement in actual benefit (IAB V, non‑existent) over other TNF inhibitors in the treatment of active psoriatic arthritis in individuals who do not respond to treatment with disease‑modifying antirheumatic drugs (DMARDs).